Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Long-Term Debt Repayments (2017 - 2021)

Protalix BioTherapeutics (PLX) has 4 years of Long-Term Debt Repayments data on record, last reported at $4.1 million in Q1 2021.

  • For Q1 2021, Long-Term Debt Repayments changed N/A year-over-year to $4.1 million; the TTM value through Dec 2021 reached $4.1 million, changed N/A, while the annual FY2024 figure was $20.4 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $4.1 million in Q1 2021 per PLX's latest filing, up from $430000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $6.7 million in Q1 2017 and bottomed at $11668.0 in Q1 2018.
  • Average Long-Term Debt Repayments over 4 years is $2.8 million, with a median of $2.5 million recorded in 2018.
  • The widest YoY moves for Long-Term Debt Repayments: up 99.83% in 2018, down 99.83% in 2018.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $6.7 million in 2017, then tumbled by 62.38% to $2.5 million in 2018, then crashed by 83.0% to $430000.0 in 2020, then skyrocketed by 850.23% to $4.1 million in 2021.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $4.1 million in Q1 2021, $430000.0 in Q3 2020, and $2.5 million in Q2 2018.